Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.470
+0.010 (0.68%)
At close: Oct 8, 2025, 4:00 PM EDT
1.470
0.00 (0.00%)
After-hours: Oct 8, 2025, 7:52 PM EDT

Company Description

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics.

It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.

The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022.

Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Revelation Biosciences, Inc.
Revelation Biosciences logo
CountryUnited States
Founded2020
IndustryBiotechnology
SectorHealthcare
Employees9
CEOJames Rolke

Contact Details

Address:
4660 La Jolla Village Drive, Suite 100
San Diego, California 92122
United States
Phone(650) 800-3717
Websiterevbiosciences.com

Stock Details

Ticker SymbolREVB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001810560
CUSIP Number76135L705
ISIN NumberUS76135L7055
Employer ID84-3898466
SIC Code2834

Key Executives

NamePosition
James M. RolkeChairman and Chief Executive Officer
Chester Stanley Zygmont IIIChief Financial Officer and Corporate Secretary
Sandra VedrickVice President of Human Resources and Investor Relations
Carol OdleSenior Director of Clinical Projects

Latest SEC Filings

DateTypeTitle
Sep 30, 2025EFFECTNotice of Effectiveness
Sep 30, 2025424B3Prospectus
Sep 30, 2025S-3/A[Amend] Registration statement under Securities Act of 1933
Sep 22, 2025DEF 14AOther definitive proxy statements
Sep 16, 2025S-3Registration statement under Securities Act of 1933
Sep 15, 20258-KCurrent Report
Sep 12, 2025PRE 14AOther preliminary proxy statements
Sep 9, 20258-KCurrent Report
Aug 8, 20258-KCurrent Report
Aug 8, 202510-QQuarterly Report